Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation

• Main Authors: Kok Hoe Chan MD (Author), Ningjing Li MD (Author), Ran Lador MD (Author), Mark Amsbaugh MD (Author), Anneliese Gonzalez MD (Author), Putao Cen MD (Author)
• Format: Book
• Published: SAGE Publishing, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The Von-Hippel-Lindau (VHL) gene, acting as a tumor suppressor, plays a crucial role in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). Approximately 90% of individuals with advanced ccRCC exhibit somatic mutations in the VHL gene. Belzutifan, orally administered small-molecule inhibit...